SCHEMBL248157

SCHEMBL248157

Cc1c(N2CCCC2=O)nc2c(Cl)cccc2c1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.43
NR4A2 P43354 2/20 0.42
PARP1 P09874 1/20 0.41
ACHE P22303 1/20 0.39
PDE10A Q9Y233 1/20 0.38
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
ATM Q13315 1/20 0.37
KCNH2 Q12809 2/20 0.35
HRH3 Q9Y5N1 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
DHODH Q02127 1/20 0.35
BRD4 O60885 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2123588 0.73 PIK3CA (0.49) ACHEPDE10ANPC1MAPTRAB9A
SCHEMBL2124160 0.73 PARP1 (0.39) CNR2PARP1ACHENPC1L3MBTL1
SCHEMBL2124353 0.70 PIK3CA (0.50) ACHENPC1MAPTRAB9AKCNH2
SCHEMBL247759 0.68 NR4A2 (0.50) NR4A2PARP1ACHENPC1MAPT
SCHEMBL2123532 0.68 NR4A2 (0.50) NR4A2PARP1ACHENPC1MAPT
SCHEMBL4089299 0.67 ABCB1 (0.69) MAPTL3MBTL1ATMCYP1A2CYP3A4
SCHEMBL245528 0.66 PIK3CA (0.50) NPC1RAB9AL3MBTL1FFAR1FFAR4
SCHEMBL24388818 0.65 HSD17B10 (0.50) CNR2L3MBTL1CYP1A2CYP3A4CYP2D6
SCHEMBL8560632 0.65 HSD17B10 (0.46) CNR2L3MBTL1CYP3A4CYP2C9
SCHEMBL5436101 0.64 ALOX5 (0.54) CNR2L3MBTL1ATMCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588471-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY Amgen Inc. (US) 2013-05-08 EP disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 CNR2 1496/4885NR4A2 3167/4885PARP1 978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.